Relacorilant
 | |
| Clinical data | |
|---|---|
| Trade names | Lifyorli |
| Other names | CORT-125134 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a626056 |
| License data |
|
| Routes of administration | By mouth |
| Drug class | Antiglucocorticoid |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C27H22F4N6O3S |
| Molar mass | 586.57 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Relacorilant, sold under the brand name Lifyorli, is an anti-cancer medication used for the treatment of ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.[1] Relacorilant is a glucocorticoid receptor antagonist.[1] It is taken by mouth.[1]
The most common adverse reactions include decreased hemoglobin, decreased neutrophils, fatigue, nausea, diarrhea, decreased platelets, rash, and decreased appetite.[2]
Relacorilant was approved for medical use in the United States in March 2026.[2]
Medical uses
[edit]Relacorilant is indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.[1]
Adverse effects
[edit]The US prescribing information includes a contraindication for people who require corticosteroids for a lifesaving indication as well as warnings and precautions for neutropenia and severe infections, adrenal insufficiency, exacerbation of conditions treated with glucocorticoids, and embryo-fetal toxicity.[2] The most common adverse reactions include decreased hemoglobin, decreased neutrophils, fatigue, nausea, diarrhea, decreased platelets, rash, and decreased appetite.[2]
History
[edit]Efficacy was evaluated in ROSELLA (NCT05257408), a multi-center, open-label, trial in 381 participants with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.[2] Participants were permitted to receive up to three prior lines of systemic therapy and prior bevacizumab was required.[2] The trial excluded participants who required chronic or frequent use of glucocorticoids.[2] Participants were randomized (1:1) to receive relacorilant in combination with nab-paclitaxel or nab-paclitaxel alone.[2]
Society and culture
[edit]Legal status
[edit]Relacorilant was approved for medical use in the United States in March 2026.[3]
Names
[edit]Relacorilant is the international nonproprietary name.[4]
References
[edit]- 1 2 3 4 5 "Lifyorli- relacorilant kit". DailyMed. 26 March 2026. Retrieved 1 April 2026.
- 1 2 3 4 5 6 7 8 9 "FDA approves relacorilant with nab-paclitaxel for platinum-resistant". U.S. Food and Drug Administration (FDA). 25 March 2026. Retrieved 5 April 2026.
This article incorporates text from this source, which is in the public domain. - ↑ Kansteiner F (25 March 2026). "Corcept's lead drug bounces back from FDA snub with different approval as Lifyorli in ovarian cancer". Fierce Pharma. Retrieved 26 March 2026.
- ↑ World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 78". WHO Drug Information. 31 (3). hdl:10665/330961.
- ↑ "FDA Approves Corcept's Selective Glucocorticoid Receptor Antagonist Lifyorli (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer" (Press release). Corcept. Retrieved 26 July 2026 – via Business Wire.
External links
[edit]- Clinical trial number NCT05257408 for "Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer" at ClinicalTrials.gov
